Septodont OraVerse Local Anesthesia Reversal Agent

Description

OraVerse Local Anesthesia Reversal Agent. Box containing 1 blister of 10 x 1.7

Features & benefits

  • OraVerse is the first and only local anesthesia reversal agent
  • In clinical trials, the median time to recovery of normal sensation in the upper lip was 50 minutes for OraVerse patients vs. 133 minutes for the control group and in the lower lip was 70 minutes for OraVerse patients vs. 155 minutes for the control.
  • In clinical trials, OraVerse patients were more quickly able to smile, speak, drink normally and minimize drooling.
  • Market research shows 88% of patients may be interested in receiving a product like OraVerse1

Presentation

  • Item #99210 – Box containing 1 blister of 10 x 1.7ml glass cartridges

Risk information

  • In clinical trials, the most common adverse events with OraVerse (phentolamine mesylate) vs. control were post-procedural pain (6% vs. 6%), injection site pain (5% vs. 4%), tachycardia (5% vs. 6%), bradycardia (2% vs. 0.3%) and headache (3% vs. 4%). Following parenteral use of phentolamine in non-dental indications, myocardial infarction and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states. Although such effects are uncommon with OraVerse, clinicians should be alert to the signs and symptoms of tachycardia and cardiac arrhythmias, particularly in patients with a history of cardiovascular disease, as these symptoms may occur with the use of phentolamine or other alpha-adrenergic blocking agents.
Product form

OraVerse Local Anesthesia Reversal Agent. Box containing 1 blister of 10 x 1.7 Features & benefits OraVerse is the first... Read more

Free pickup in our shop(s)

SKU: 99210

$79.99 $72.99 Excl. VAT

  • Shipped today? Order within: Oct 04, 2023 17:00:00 -0400
Shipping information

Order processing time:

1-2 business days for order to process and shipped.

Delivery carriers:

UPS, FedEx and USPS. Tracking details will be provided to the customer via email.

Returns:


SurgiMac brand Products returns - If you are unsatisfied with your SurgiMac order, we offer a no risk return policy. Within 30 days of receipt, you may return your new and unused product in its resalable condition for a full refund minus the cost of the shipping label. A restocking fee may apply. For customized items, a refund may be issued if there was an error on our end. Unfortunately, all sales of infection control products are final and not eligible for a refund. Other brands - Brands other than SurgiMac, we will provide credit after we receive credit from the manufacturer. Our representative will serve as your advocate to resolve any issues quickly and fairly. If the manufacturer agrees that the product needs to be returned or replaced, we will provide the necessary installation services at no extra cost. Any manufacturer’s restocking fee will be your responsibility. Instructions: Inspect your order as soon as it arrives. To arrange a return, have your order number ready and reach out to us via live chat or email (info@surgimac.com). We'll get back to you within one business day with the next steps for obtaining a return authorization.

Ask a question

Description

OraVerse Local Anesthesia Reversal Agent. Box containing 1 blister of 10 x 1.7

Features & benefits

  • OraVerse is the first and only local anesthesia reversal agent
  • In clinical trials, the median time to recovery of normal sensation in the upper lip was 50 minutes for OraVerse patients vs. 133 minutes for the control group and in the lower lip was 70 minutes for OraVerse patients vs. 155 minutes for the control.
  • In clinical trials, OraVerse patients were more quickly able to smile, speak, drink normally and minimize drooling.
  • Market research shows 88% of patients may be interested in receiving a product like OraVerse1

Presentation

  • Item #99210 – Box containing 1 blister of 10 x 1.7ml glass cartridges

Risk information

  • In clinical trials, the most common adverse events with OraVerse (phentolamine mesylate) vs. control were post-procedural pain (6% vs. 6%), injection site pain (5% vs. 4%), tachycardia (5% vs. 6%), bradycardia (2% vs. 0.3%) and headache (3% vs. 4%). Following parenteral use of phentolamine in non-dental indications, myocardial infarction and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states. Although such effects are uncommon with OraVerse, clinicians should be alert to the signs and symptoms of tachycardia and cardiac arrhythmias, particularly in patients with a history of cardiovascular disease, as these symptoms may occur with the use of phentolamine or other alpha-adrenergic blocking agents.

Recently viewed products

Login

Forgot your password?

Don't have an account yet?
Create account